HCPCS code lookup
HCPCS Level II
Q2053
Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Ask Rivvi
- Code
- Q2053
- Description
- Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
NDC crosswalk
- 71287-0219-01 Tecartus, Gilead Sciences, Inc.. Billable units per 11-digit NDC: 1.
- 71287-0220-01 Tecartus, Gilead Sciences, Inc.. Billable units per 11-digit NDC: 1.
Source: CMS ASP NDC-HCPCS crosswalk, effective October 1, 2026 through December 31, 2026.